A Phase 2 interventional study of INC424 in Graft vs Host Disease, sponsored by Novartis Pharmaceuticals. Completed at 21 sites in 14 countries. Open to participants aged 28 Days to 17 Years. Per ClinicalTrials.gov, last updated 2025-12-11.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing ruxolitinib in Graft vs Host Disease — 13 open to participants now, 16 under way, 2 of them phase 3. ruxolitinib · Graft vs Host Disease.
Among the 27 studies testing ruxolitinib in Graft vs Host Disease, this one is the 17th largest by enrollment, is one of 2 that started in 2020, is one of 13 in phase 2, and was the 9th registered.
804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.
Browse Graft vs Host Disease studies →13 of the 27 studies testing ruxolitinib in Graft vs Host Disease are open now, in 12 countries. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Bambino Gesù Hospital and Research Institute · Sites in Austria, Czechia, Denmark and 6 more countries
Ages 3 mo–25 yrs
Novartis Pharmaceuticals · Sites in China
Ages 12–100
By country, each count listing its studies:
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.
This study: 28 Days to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 17 · Phase 3 4 · Phase 4 3
First in 2015; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is above the median of 35 across 639 interventional studies indexed under Graft vs Host Disease.
Median enrollment 54 across the 27 interventional studies. Of the 11 that completed or were terminated, 7 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 27 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
12 studies in Graft vs Host Disease by Novartis: 2 open now, 4 under way, none of them phase 3. Of 8 finished, 7 (88%) have results posted.
Among the 12 studies in Graft vs Host Disease by Novartis, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2020, is the only one in phase 2, and was the 8th registered.
Novartis’s Graft vs Host Disease studies by the year they started, since 2012.
6 of the studies testing ruxolitinib in Graft vs Host Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07238712St. Petersburg State Pavlov Medical UniversityOptimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor | 2026-12-10 |
| NCT06936566John LevineMAGIC Ruxolitinib for aGVHD | 2027-06-01 |
| NCT06008808Washington University School of MedicineRuxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation | 2027-09-08 |
| NCT07796620Peking University People's HospitalSirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNI | 2027-09-30 |
| NCT07356245Ohio State University Comprehensive Cancer CenterRuxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma | 2027-10-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 27 studies testing ruxolitinib in Graft vs Host Disease, from their registry updates:
Among Novartis’s 12 in Graft vs Host Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This open-label, single-arm, Phase II multi-center study enrolled 46 participants and investigated the activity, pharmacokinetics and safety of ruxolitinib added to the subject's immunosuppressive regimen among infants, children, and adolescents aged ≥28 days to \<18 years old with either moderate to severe treatment-naive cGvHD or SR-cGvHD.
Although 46 participants were enrolled,1 participant (enrolled in the ≥6y to \<12y age group) received study treatment beyond protocol requirements and was excluded from analyses.
Subjects were grouped according to their age as follows:
After a screening period of Day -28 to Day -1: eligible subjects started study treatment on Cycle
1 Day 1 and were treated for up to a maximum of 3 years (39 cycles/156 weeks) or until early discontinuation. Subjects who discontinued study treatment for any reason earlier than 39 cycles were followed every 6 months until 3 years from their first dose of study treatment was reached.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects with diagnosed moderate to severe cGvHD according to NIH 2014 Consensus Criteria prior to Cycle 1 Day 1. Other possible diagnoses for clinical symptoms supporting cGvHD diagnoses must be excluded (e.g., infection, drug side effects, ). Subjects must be either:
OR o Steroid- moderate to severe cGvHD as per institutional criteria, or per physician decision in case institutional criteria are not available, and still receiving systemic corticosteroids for the treatment of cGvHD for a duration of \<18 months prior to Cycle 1 Day 1. In case the corticosteroids were previously interrupted due to response, the duration of \< 18 months applies to the last period of corticosteroid use.
Exclusion Criteria:
SR-cGvHD subjects with a prior cGvHD treatment with a JAK1- or a JAK2- or a JAK1/2-inhibitor, except when the subject achieved complete or partial response and has been off JAK inhibitor treatment for at least 4 weeks prior to Cycle Day 1 or up to 5 times the half-life of the prior JAK inhibitor, whichever is longer.
* Subjects who initiated systemic calcineurin inhibitors (CNI; cyclosporine or tacrolimus) within 3 weeks prior to start of ruxolitinib on Cycle 1 Day 1. Note: systemic CNI are allowed when initiated > 3 weeks from start of ruxolitinib.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All pediatric participants received ruxolitinib twice a day (BID) in either tablet or oral solution (liquid), depending on the group they were in.
Drug: INC424
Ruxolitinib was taken orally based on age groups as follows: Group 1 (\>=12y to \<18y): 10mg bid as tablet Group 2 (\>=6y to \<12y): 5mg bid as tablet or liquid Group 3 (\>=2y to \<6y): 4mg/m2 bid as liquid
Also known as: Ruxolitinib
Overall Response Rate (ORR) at Cycle 7 Day 1
ORR is defined as the percentage of participants demonstrating a complete response (CR) or partial response (PR) without the requirement of additional systemic therapies for an earlier progression, mixed response or non-response. The response is assessed per National Institute of Health (NIH) consensus criteria and scoring of response was relative to the organ stage at the start of study treatment.
Time frame: At Cycle 7 Day 1 (Day 168); Cycle = 28 Days
Ruxolitinib Concentrations by Timepoint
Pharmacokinetics (PK) of ruxolitinib by age groups (and formulation tablet vs liquid).
Time frame: Cycle 1 Day 1: 0.5, 2 and 6 hours post-dose; Pre-dose on Cycle 1 Day 8, Cycle 1 Day 15, Cycle 1 Day 22, Cycle 3 Day 1, Cycle 5 Day 1 and Cycle 7 Day 1; Cycle = 28 Days
Duration of Response (DOR)
Time from first response until chronic Graft vs. host disease (cGvHD) progression, death, or the date of addition of systemic therapies for cGvHD assessed for responders only based on BOR up to Cycle 7 Day 1. Presented as percentage of participants to still be in response at different time points in months (per Kaplan-Meier estimates). Participants without event will be censored at the date of their last response assessment prior to or at the analysis cut-off date if no events occurred on or before 12 weeks (84 days) after the last GvHD assessment. As planned in the SAP, this outcome measure is provided for all participants instead of per age groups.
Time frame: From baseline up to 39 cycles; Cycle = 28 Days
Overall Response Rate (ORR) at Cycle 4 Day 1
ORR is defined as the percentage of participants demonstrating a complete response (CR) or partial response (PR) without the requirement of additional systemic therapies for an earlier progression, mixed response or non-response. The response is assessed per National Institute of Health (NIH) consensus criteria and scoring of response will be relative to the organ stage at the start of study treatment at Cycle 4 Day 1.
Time frame: At Cycle 4 Day 1 (Day 84); Cycle = 28 Days
Best Overall Response (BOR)
Percentage of participants who achieved overall response (complete response (CR) or partial response (PR)) at any time point until Cycle 7 Day 1 or the start of additional systemic therapy for chronic GvHD.
Time frame: Until Cycle 7 Day 1 (Day 168) or the start of additional systemic therapy for cGvHD; Cycle = 28 Days
Failure Free Survival (FFS)
Failure-free survival was defined as the time from date of treatment to any of the following events: i) relapse or recurrence of underlying disease or death due to underlying disease, ii) non-relapse mortality, or iii) addition or initiation of another systemic therapy for cGvHD per Kaplan-Meier estimates. As planned in the SAP, this outcome measure is provided for all participants instead of per age groups.
Time frame: From baseline up to 39 cycles; Cycle = 28 Days
Cumulative Incidence of Malignancy Relapse/Recurrence (MR)
MR was defined as the time from date of treatment assignment to the date of hematologic malignancy relapse/recurrence. Calculated for subjects with underlying hematologic malignant disease. The cumulative incidence (CI) of malignancy relapse/recurrence at 1, 2, 6, 12, 18, 24, 30 and 36 months after start of treatment has been reported. As planned in the SAP, this outcome measure is provided for all participants instead of per age groups.
Time frame: From baseline up to 39 cycles; Cycle = 28 Days
Non-relapse Mortality (NRM)
NRM is defined as the time from date of treatment assignment to date of death not preceded by underlying disease relapse/recurrence calculated for all participants. The cumulative incidence (CI) of non-relapse mortality at 1, 2, 6, 12, 18, 24, 30 and 36 months after start of treatment has been reported. As planned in the SAP, this outcome measure is provided for all participants instead of per age groups.
Time frame: From baseline up to 39 cycles; Cycle = 28 Days
Overall Survival (OS)
OS is defined as the time from the date of treatment assignment to the date of death due to any cause. As planned in the SAP, this outcome measure is provided for all participants instead of per age groups.
Time frame: From baseline up to 39 cycles; Cycle = 28 Days
Percentage of Participants With ≥50% Reduction From Baseline in Daily Corticosteroid Dose
Reduction of at least ≥50% from baseline in daily corticosteroid use by Cycle 7 Day 1 (regardless of reason). As planned in the SAP, this outcome measure is provided for all participants instead of per age groups, for those who received corticosteroids at baseline.
Time frame: Baseline to Cycle 7 Day 1 (Day 168); Cycle = 28 Days
Percentage of Participants With a Reduction to a Low Dose Corticosteriod
Reduction to low dose corticosteroids, is defined as the percentage of participants with reduction from baseline in daily corticosteroid dose to methylprednisolone-equivalent steroid dose of ≤ 0.2 mg/kg/day (or equivalent dose of ≤ 0.25 mg/kg/day prednisone or prednisolone). As planned in the SAP, this outcome measure is provided for all participants instead of per age groups, for those who received corticosteroids at baseline.
Time frame: Baseline to Cycle 7 Day 1 (Day 168); Cycle = 28 Days
Graft Failure
Reported are the number of participants with graft failure from all age groups together. Graft failure was assessed by donor cell chimerism, defined as initial whole blood or marrow donor chimerism for those who had ≥ 5% donor cell chimerism at baseline. If donor cell chimerism declined to \< 5% on subsequent measurements, graft failure was declared. As planned in the SAP, this outcome measure is provided for all participants instead of per age groups.
Time frame: From baseline up to 39 cycles; Cycle = 28 Days
At least 5 evaluable participants per group were needed for the primary analysis in Groups 1, 2 and 3. No minimum number of evaluable participants were needed in Group 4. Disposition and Demographics are presented by age group.
| Milestone | ≥ 12y - < 18y RUX 10mg BID (Group 1) | ≥ 6y - < 12y RUX 5mg BID (Group 2) | ≥ 2y - < 6y RUX 4mg/m2 BID (Group 3) |
|---|---|---|---|
| Started | 22 | 17 | 7 |
| Full analysis set | 22 | 16 | 7 |
| Completed treatment | 3 | 5 | 3 |
| Discontinued from treatment | 19 | 11 | 4 |
| Participants who received tablets | 22 | 14 | 0 |
| Participants who received liquid | 0 | 2 | 7 |
| Completed | 14 | 10 | 4 |
| Not completed | 8 | 7 | 3 |
| Withdrew: Death | 6 | 3 | 2 |
| Withdrew: Subject decision | 0 | 3 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 |
| Withdrew: Guardian decision | 0 | 0 | 1 |
| Withdrew: Enrolled but received treatment beyond protocol requirement | 0 | 1 | 0 |
ORR is defined as the percentage of participants demonstrating a complete response (CR) or partial response (PR) without the requirement of additional systemic therapies for an earlier progression, mixed response or non-response. The response is assessed per National Institute of Health (NIH) consensus criteria and scoring of response was relative to the organ stage at the start of study treatment.
| Percentage of participants | ≥ 12y - < 18y RUX 10mg BID (Group 1) | ≥ 6y - < 12y RUX 5mg BID (Group 2) | ≥ 2y - < 6y RUX 4mg/m2 BID (Group 3) | All Participants |
|---|---|---|---|---|
| Overall Response Rate (ORR) at Cycle 7 Day 1 | 36.4 (19.6 to 56.1) | 50.0 (27.9 to 72.1) | 28.6 (5.3 to 65.9) | 40.0 (27.7 to 53.3) |
Pharmacokinetics (PK) of ruxolitinib by age groups (and formulation tablet vs liquid).
| ug/ml | ≥ 12y - < 18y RUX 10mg BID (Tablet) | ≥ 6y - < 12y RUX 5mg BID (Tablet) | ≥ 6y - < 12y RUX 5mg BID (Liquid) | ≥ 2y - < 6y RUX 4mg/m2 BID (Liquid) |
|---|---|---|---|---|
| Cycle 1 Day 1: 0.5 hour (hr) (post-dose) | 60.0 ± 350.7 | 32.4 ± 471.9 | 78.6 | 60.1 ± 98.7 |
| Cycle 1 Day 1: 2 hr (post-dose) | 112 ± 51.8 | 106 ± 39.2 | 77.0 | 49.7 ± 30.7 |
| Cycle 1 Day 1: 6hr (post-dose) | 56.7 ± 73.9 | 47.8 ± 164.1 | 60.0 | 15.3 ± 66.2 |
| Cycle 1 Day 8: 0 hr (pre-dose) | 16.7 ± 208.3 | 10.9 ± 146.5 | 3.47 | 3.88 ± 152.4 |
| Cycle 1 Day 15: 0 hr (pre-dose) | 17.8 ± 195.5 | 12.9 ± 248.2 | 4.14 ± 399.3 | 9.43 ± 121.5 |
| Cycle 1 Day 22: 0 hr (pre-dose) | 20.8 ± 199.5 | 11.7 ± 165.4 | 4.89 ± 505.2 | 10.3 ± 150.4 |
| Cycle 3 Day 1: 0 hr (pre-dose | 11.4 ± 193.8 | 11.3 ± 193.1 | 2.66 ± 587.5 | 5.56 ± 180.8 |
| Cycle 5 Day 1: 0 hr (pre-dose | 13.0 ± 176.6 | 16.4 ± 470.7 | 11.0 ± 83.5 | 7.32 ± 102.0 |
| Cycle 7 Day 1: 0 hr (pre-dose | 14.3 ± 173.7 | 10.7 ± 129.9 | 5.79 ± 120.1 | 4.94 ± 165.9 |
Time from first response until chronic Graft vs. host disease (cGvHD) progression, death, or the date of addition of systemic therapies for cGvHD assessed for responders only based on BOR up to Cycle 7 Day 1. Presented as percentage of participants to still be in response at different time points in months (per Kaplan-Meier estimates). Participants without event will be censored at the date of their last response assessment prior to or at the analysis cut-off date if no events occurred on or before 12 weeks (84 days) after the last GvHD assessment. As planned in the SAP, this outcome measure is provided for all participants instead of per age groups.
| Percentage of participants | All Participants |
|---|---|
| Month 1 | 94.59 (80.07 to 98.62) |
| Month 2 | 86.23 (70.01 to 94.03) |
| Month 6 | 74.24 (56.17 to 85.74) |
| Month 12 | 63.10 (43.74 to 77.38) |
| Month 18 | 58.89 (39.23 to 74.12) |
| Month 24 | 58.89 (39.23 to 74.12) |
| Month 30 | 58.89 (39.23 to 74.12) |
| Month 36 | 58.89 (39.23 to 74.12) |
ORR is defined as the percentage of participants demonstrating a complete response (CR) or partial response (PR) without the requirement of additional systemic therapies for an earlier progression, mixed response or non-response. The response is assessed per National Institute of Health (NIH) consensus criteria and scoring of response will be relative to the organ stage at the start of study treatment at Cycle 4 Day 1.
| Percentage of participants | ≥ 12y - < 18y RUX 10mg BID (Group 1) | ≥ 6y - < 12y RUX 5mg BID (Group 2) | ≥ 2y - < 6y RUX 4mg/m2 BID (Group 3) | All Participants |
|---|---|---|---|---|
| Overall Response Rate (ORR) at Cycle 4 Day 1 | 54.5 (35.3 to 72.9) | 62.5 (39.1 to 82.2) | 42.9 (12.9 to 77.5) | 55.6 (42.3 to 68.3) |
Percentage of participants who achieved overall response (complete response (CR) or partial response (PR)) at any time point until Cycle 7 Day 1 or the start of additional systemic therapy for chronic GvHD.
| Percentage of participants | ≥ 12y - < 18y RUX 10mg BID (Group 1) | ≥ 6y - < 12y RUX 5mg BID (Group 2) | ≥ 2y - < 6y RUX 4mg/m2 BID (Group 3) | All Participants |
|---|---|---|---|---|
| Best Overall Response (BOR) | 81.8 (63.1 to 93.5) | 81.3 (58.3 to 94.7) | 85.7 (47.9 to 99.3) | 82.2 (70.2 to 90.8) |
Failure-free survival was defined as the time from date of treatment to any of the following events: i) relapse or recurrence of underlying disease or death due to underlying disease, ii) non-relapse mortality, or iii) addition or initiation of another systemic therapy for cGvHD per Kaplan-Meier estimates. As planned in the SAP, this outcome measure is provided for all participants instead of per age groups.
| Percentage of participants | All Participants |
|---|---|
| Month 1 | 91.11 (78.03 to 96.57) |
| Month 2 | 84.44 (70.12 to 92.26) |
| Month 6 | 68.89 (53.20 to 80.25) |
| Month 12 | 64.44 (48.67 to 76.48) |
| Month 18 | 57.78 (42.11 to 70.61) |
| Month 24 | 57.78 (42.11 to 70.61) |
| Month 30 | 57.78 (42.11 to 70.61) |
| Month 36 | 57.78 (42.11 to 70.61) |
MR was defined as the time from date of treatment assignment to the date of hematologic malignancy relapse/recurrence. Calculated for subjects with underlying hematologic malignant disease. The cumulative incidence (CI) of malignancy relapse/recurrence at 1, 2, 6, 12, 18, 24, 30 and 36 months after start of treatment has been reported. As planned in the SAP, this outcome measure is provided for all participants instead of per age groups.
| Percentage of participants | All Participants |
|---|---|
| Month 1 | 3.33 (0.23 to 14.80) |
| Month 2 | 10.00 (2.47 to 23.88) |
| Month 6 | 10.00 (2.47 to 23.88) |
| Month 12 | 10.00 (2.47 to 23.88) |
| Month 18 | 10.00 (2.47 to 23.88) |
| Month 24 | 10.00 (2.47 to 23.88) |
| Month 30 | 10.00 (2.47 to 23.88) |
| Month 36 | 10.00 (2.47 to 23.88) |
NRM is defined as the time from date of treatment assignment to date of death not preceded by underlying disease relapse/recurrence calculated for all participants. The cumulative incidence (CI) of non-relapse mortality at 1, 2, 6, 12, 18, 24, 30 and 36 months after start of treatment has been reported. As planned in the SAP, this outcome measure is provided for all participants instead of per age groups.
| Percentage of participants | All Participants |
|---|---|
| Month 1 | 2.22 (0.17 to 10.28) |
| Month 2 | 2.22 (0.17 to 10.28) |
| Month 6 | 6.67 (1.70 to 16.53) |
| Month 12 | 13.33 (5.34 to 25.02) |
| Month 18 | 17.78 (8.23 to 30.28) |
| Month 24 | 20.07 (9.80 to 32.93) |
| Month 30 | 20.07 (9.80 to 32.93) |
| Month 36 | 20.07 (9.80 to 32.93) |
OS is defined as the time from the date of treatment assignment to the date of death due to any cause. As planned in the SAP, this outcome measure is provided for all participants instead of per age groups.
| survival probability in percentage | All Participants |
|---|---|
| Month 1 | 97.78 (85.25 to 99.68) |
| Month 2 | 97.78 (85.25 to 99.68) |
| Month 6 | 91.06 (77.90 to 96.55) |
| Month 12 | 84.23 (69.73 to 92.15) |
| Month 18 | 79.67 (64.57 to 88.87) |
| Month 24 | 77.33 (61.94 to 87.11) |
| Month 30 | 77.33 (61.94 to 87.11) |
| Month 36 | 74.91 (59.26 to 85.26) |
Reduction of at least ≥50% from baseline in daily corticosteroid use by Cycle 7 Day 1 (regardless of reason). As planned in the SAP, this outcome measure is provided for all participants instead of per age groups, for those who received corticosteroids at baseline.
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With ≥50% Reduction From Baseline in Daily Corticosteroid Dose | 75.0 |
Reduction to low dose corticosteroids, is defined as the percentage of participants with reduction from baseline in daily corticosteroid dose to methylprednisolone-equivalent steroid dose of ≤ 0.2 mg/kg/day (or equivalent dose of ≤ 0.25 mg/kg/day prednisone or prednisolone). As planned in the SAP, this outcome measure is provided for all participants instead of per age groups, for those who received corticosteroids at baseline.
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With a Reduction to a Low Dose Corticosteriod | 67.5 |
Reported are the number of participants with graft failure from all age groups together. Graft failure was assessed by donor cell chimerism, defined as initial whole blood or marrow donor chimerism for those who had ≥ 5% donor cell chimerism at baseline. If donor cell chimerism declined to \< 5% on subsequent measurements, graft failure was declared. As planned in the SAP, this outcome measure is provided for all participants instead of per age groups.
| Participants | All Participants |
|---|---|
| Graft Failure | 2 |
Collected over Adverse events (AEs) and on-treatment deaths were collected from the first dose of study treatment up to 30 days after last dose of study medication. Post-treatment survival follow-up deaths were collected 31 days after last dose of study medication until the end of the study, up to approx. 36 months/39 cycles.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| On-Treatment >=12y - <18y RUX 10mg BID | 0/22 (0%) | 15/22 (68.2%) | 22/22 (100%) |
| On-Treatment >=6y - <12y RUX 5mg BID | 2/16 (12.5%) | 7/16 (43.8%) | 15/16 (93.8%) |
| On-Treatment >=2y - <6y RUX 4mg/m2 BID | 1/7 (14.3%) | 4/7 (57.1%) | 7/7 (100%) |
| On-Treatment - All Participants | 3/45 (6.7%) | 26/45 (57.8%) | 44/45 (97.8%) |
| Post-Treatment >=12y - <18y RUX 10mg BID | 6/22 (27.3%) | 3/22 (13.6%) | 4/22 (18.2%) |
| Post-Treatment >=6y - <12y RUX 5mg BID | 1/16 (6.3%) | 0/16 (0%) | 2/16 (12.5%) |
| Post-Treatment >=2y - <6y RUX 4mg/m2 BID | 1/7 (14.3%) | 0/7 (0%) | 0/7 (0%) |
| Post-Treatment All Participants | 8/45 (17.8%) | 3/45 (6.7%) | 6/45 (13.3%) |
| Event | On-Treatment >=12y - <18y RUX 10mg BID | On-Treatment >=6y - <12y RUX 5mg BID | On-Treatment >=2y - <6y RUX 4mg/m2 BID | On-Treatment - All Participants | Post-Treatment >=12y - <18y RUX 10mg BID | Post-Treatment >=6y - <12y RUX 5mg BID | Post-Treatment >=2y - <6y RUX 4mg/m2 BID | Post-Treatment All Participants |
|---|---|---|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 0/22 | 0/16 | 1/7 | 1/45 | 0/22 | 0/16 | 0/7 | 0/45 |
| PyrexiaGeneral disorders | 2/22 | 0/16 | 1/7 | 3/45 | 0/22 | 0/16 | 0/7 | 0/45 |
| Aspergillus infectionInfections and infestations | 0/22 | 0/16 | 1/7 | 1/45 | 0/22 | 0/16 | 0/7 | 0/45 |
| Human bocavirus infectionInfections and infestations | 0/22 | 0/16 | 1/7 | 1/45 | 0/22 | 0/16 | 0/7 | 0/45 |
| Parainfluenzae virus infectionInfections and infestations | 0/22 | 0/16 | 1/7 | 1/45 | 0/22 | 0/16 | 0/7 | 0/45 |
| Pneumonia viralInfections and infestations | 0/22 | 0/16 | 1/7 | 1/45 | 0/22 | 0/16 | 0/7 | 0/45 |
| Rhinovirus infectionInfections and infestations | 0/22 | 0/16 | 1/7 | 1/45 | 0/22 | 0/16 | 0/7 | 0/45 |
| Tooth infectionInfections and infestations | 0/22 | 0/16 | 1/7 | 1/45 | 0/22 | 0/16 | 0/7 | 0/45 |
| Upper respiratory tract infectionInfections and infestations | 0/22 | 0/16 | 1/7 | 1/45 | 0/22 | 0/16 | 0/7 | 0/45 |
| COVID-19Infections and infestations | 2/22 | 0/16 | 0/7 | 2/45 | 1/22 | 0/16 | 0/7 | 1/45 |
| Event | On-Treatment >=12y - <18y RUX 10mg BID | On-Treatment >=6y - <12y RUX 5mg BID | On-Treatment >=2y - <6y RUX 4mg/m2 BID | On-Treatment - All Participants | Post-Treatment >=12y - <18y RUX 10mg BID | Post-Treatment >=6y - <12y RUX 5mg BID | Post-Treatment >=2y - <6y RUX 4mg/m2 BID | Post-Treatment All Participants |
|---|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 1/22 | 4/16 | 4/7 | 9/45 | 0/22 | 0/16 | 0/7 | 0/45 |
| AnaemiaBlood and lymphatic system disorders | 7/22 | 2/16 | 2/7 | 11/45 | 0/22 | 0/16 | 0/7 | 0/45 |
| NeutropeniaBlood and lymphatic system disorders | 2/22 | 4/16 | 2/7 | 8/45 | 0/22 | 0/16 | 0/7 | 0/45 |
| COVID-19Infections and infestations | 4/22 | 3/16 | 2/7 | 9/45 | 0/22 | 0/16 | 0/7 | 0/45 |
| Neutrophil count decreasedInvestigations | 5/22 | 2/16 | 2/7 | 9/45 | 0/22 | 0/16 | 0/7 | 0/45 |
| PyrexiaGeneral disorders | 3/22 | 4/16 | 0/7 | 7/45 | 0/22 | 0/16 | 0/7 | 0/45 |
| Platelet count decreasedInvestigations | 5/22 | 2/16 | 0/7 | 7/45 | 1/22 | 0/16 | 0/7 | 1/45 |
| HeadacheNervous system disorders | 5/22 | 2/16 | 0/7 | 7/45 | 1/22 | 0/16 | 0/7 | 1/45 |
| NasopharyngitisInfections and infestations | 1/22 | 3/16 | 1/7 | 5/45 | 0/22 | 0/16 | 0/7 | 0/45 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/22 | 3/16 | 0/7 | 6/45 | 1/22 | 0/16 | 0/7 | 1/45 |
Full Analysis Set (FAS) comprised all subjects to whom study treatment has been assigned and who received at least one dose of study treatment.
| Age, Continuous(months) | ≥ 12y - < 18y RUX 10mg BID (Group 1) | ≥ 6y - < 12y RUX 5mg BID (Group 2) | ≥ 2y - < 6y RUX 4mg/m2 BID (Group 3) | Total |
|---|---|---|---|---|
| Mean | 175.2 ± 20.05 | 99.3 ± 18.39 | 47.1 ± 15.08 | 128.3 ± 52.86 |
| Sex: Female, Male(Participants) | ≥ 12y - < 18y RUX 10mg BID (Group 1) | ≥ 6y - < 12y RUX 5mg BID (Group 2) | ≥ 2y - < 6y RUX 4mg/m2 BID (Group 3) | Total |
|---|---|---|---|---|
| Female | 7 | 7 | 2 | 16 |
| Male | 15 | 9 | 5 | 29 |
| Race/Ethnicity, Customized(Participants) | ≥ 12y - < 18y RUX 10mg BID (Group 1) | ≥ 6y - < 12y RUX 5mg BID (Group 2) | ≥ 2y - < 6y RUX 4mg/m2 BID (Group 3) | Total |
|---|---|---|---|---|
| White | 8 | 10 | 3 | 21 |
| Black or African American | 0 | 1 | 0 | 1 |
| Asian | 14 | 5 | 4 | 23 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from May 2020 to primary completion in Feb 2022, 21 months.
Results were first posted in Apr 2025, 3 years 1 month after primary completion.
Of 102 phase 2 interventional studies under Graft vs Host Disease, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 87. This study's 21 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib